<p style="text-align:justify">Scientists at Osaka Metropolitan University have developed an efficient, non-invasive, and pain-free method to generate canine-induced pluripotent stem cells (iPSCs). They identified six reprogramming genes that can boost canine iPSC generation by 120 times compared to conventional methods using fibroblasts. The iPSCs were created from urine-derived cells without the need for feeder cells, an impossible feat until now. Their findings are expected to advance regenerative medicine and genetic disease research in veterinary medicine.</p>
<p style="text-align:justify">A research team led by Osaka Metropolitan University focused on generative AI as an information-gathering tool in the medical field. The results showed that one of the generative AIs suggested mostly fictitious references, while the other suggested multiple references with the same level of accuracy as the researchers. The use of generative AI in literature search suggests the possibility of efficiently collecting a vast amount of medical information, provided that users are well aware that the performance of generative AI is still in its infancy and that not all information presented is necessarily reliable. It is advised to use different generative AIs depending on the type of information needed.</p>
<p style="text-align:justify">An international team of researchers led by Osaka Metropolitan University has elucidated the process by which the major flavonoids naringenin, apigenin, and genistein are metabolized in the body. These findings are fundamental in elucidating the correlation between the metabolism of flavonoids in the body and their potential health benefits.</p>
A series of prison sketches by a Japanese physician convicted, but later acquitted, of crimes against Americans during World War II were handed to the man’s family on Friday, thanks in part to two Yokosuka Naval Base employees.
<p style="text-align:justify">A research team from Osaka Metropolitan University has successfully developed a novel pneumococcal vaccine by combining the team’s proprietary mucosal vaccine technology with pneumococcal surface proteins that can cover a wide range of serotypes. Experiments were conducted using mice and macaques and it was confirmed that pneumonia caused by pneumococcal infection was clearly suppressed in the target groups of animals inoculated with the vaccine.</p>